Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKAR | P32238 | 9/20 | 0.39 |
| ▸ | CCKBR | P32239 | 9/20 | 0.39 |
| ▸ | IDH1 | O75874 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | MC4R | P32245 | 4/20 | 0.35 |
| ▸ | MC1R | Q01726 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4500228 | 1.00 | CCKAR (0.39) | CCKARCCKBRIDH1BACE1MC4R | |
| SCHEMBL4497113 | 0.91 | SLC2A1 (0.36) | CCKARCCKBRALDH1A1 | |
| SCHEMBL4497110 | 0.91 | SLC2A1 (0.36) | CCKARCCKBRALDH1A1 | |
| SCHEMBL4492795 | 0.91 | MELK (0.40) | IDH1BACE1ALDH1A1 | |
| SCHEMBL4492799 | 0.91 | MELK (0.40) | IDH1BACE1ALDH1A1 | |
| SCHEMBL2566937 | 0.89 | AAK1 (0.43) | CCKARCCKBRALDH1A1CHRNB2CHRNB4 | |
| SCHEMBL2566933 | 0.89 | AAK1 (0.43) | CCKARCCKBRALDH1A1CHRNB2CHRNB4 | |
| SCHEMBL2118820 | 0.88 | ALDH1A1 (0.40) | CCKARCCKBRALDH1A1 | |
| SCHEMBL2118815 | 0.88 | ALDH1A1 (0.40) | CCKARCCKBRALDH1A1 | |
| SCHEMBL20699292 | 0.88 | ALDH1A1 (0.40) | CCKARCCKBRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514468-B2 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-07 | — | — | US | disclosed |
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | KDR, FLT1, EGFR | CCKAR 402/4885CCKBR 976/4885IDH1 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.